169 related articles for article (PubMed ID: 36951543)
1. Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10-year, single-center, real-world study of 67 cases.
Niu L; Lv H; Zhang M; Zeng H; Fu S; Cui S; Liu Z; Yan M
Cancer Med; 2023 May; 12(9):10672-10683. PubMed ID: 36951543
[TBL] [Abstract][Full Text] [Related]
2. Prognostic evaluation of breast cancer patients with evident bone marrow metastasis.
Demir L; Akyol M; Bener S; Payzin KB; Erten C; Somali I; Can A; Dirican A; Bayoglu V; Kucukzeybek Y; Alacacioglu A; Calli AO; Tarhan MO
Breast J; 2014; 20(3):279-87. PubMed ID: 24673811
[TBL] [Abstract][Full Text] [Related]
3. Symptomatic bone marrow metastases in breast cancer: A retrospective cohort study.
Yang R; Jia L; Lu G; Lv Z; Cui J
Front Oncol; 2022; 12():1042773. PubMed ID: 36605432
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of bone marrow micrometastases with sentinel lymph node status in early-stage breast cancer.
Saha S; Ali S; Ghanem M; Soni M; Wiese D; Arora M; Singh T; Iddings D
Ann Surg Oncol; 2009 Feb; 16(2):276-80. PubMed ID: 19050967
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow micrometastases do not impact disease-free and overall survival in early stage sentinel lymph node-negative breast cancer patients.
Langer I; Guller U; Worni M; Berclaz G; Singer G; Schaer G; Fehr MK; Hess T; Viehl C; Bronz L; Schnarwyler B; Wight E; Infanger E; Burger D; Koechli OR; Zuber M;
Ann Surg Oncol; 2014 Feb; 21(2):401-7. PubMed ID: 24145993
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma.
Paolino G; Carugno A; Rongioletti F; Ponzoni M; Russo V; Sena P; Ardigò M; Costanzo A; Mercuri SR; Valenti M
Melanoma Res; 2024 Feb; 34(1):31-37. PubMed ID: 37939076
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.
Kopp HG; Krauss K; Fehm T; Staebler A; Zahm J; Vogel W; Kanz L; Mayer F
Anticancer Res; 2011 Nov; 31(11):4025-30. PubMed ID: 22110237
[TBL] [Abstract][Full Text] [Related]
8. Do bone marrow micrometastases correlate with sentinel lymph node metastases in breast cancer patients?
Trocciola SM; Hoda S; Osborne MP; Christos PJ; Levin H; Martins D; Carson J; Daly J; Simmons RM
J Am Coll Surg; 2005 May; 200(5):720-5; discussion 725-6. PubMed ID: 15848362
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow.
Schindlbeck C; Janni W; Shabani N; Rack B; Gerber B; Schmitt M; Harbeck N; Sommer H; Braun S; Friese K
Breast Cancer Res Treat; 2004 Sep; 87(1):65-74. PubMed ID: 15377852
[TBL] [Abstract][Full Text] [Related]
10. Analysis of clinicopathological characteristics and prognostic factors of early-stage human epidermal growth factor receptor 2 (HER2)-low breast cancer: Compared with HER2-0 breast cancer.
Wu Q; Yang F; Liu Y; Zhang H; Zhang S; Xin L; Xu L
Cancer Med; 2023 Oct; 12(19):19560-19575. PubMed ID: 37772432
[TBL] [Abstract][Full Text] [Related]
11. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
[TBL] [Abstract][Full Text] [Related]
12. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
13. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
Schindlbeck C; Janni W; Shabani N; Kornmeier A; Rack B; Rjosk D; Gerber B; Braun S; Sommer H; Friese K
J Cancer Res Clin Oncol; 2005 Aug; 131(8):539-46. PubMed ID: 15887027
[TBL] [Abstract][Full Text] [Related]
14. Analysis of clinicopathological features and prognostic factors of breast cancer brain metastasis.
Chen YR; Xu ZX; Jiang LX; Dong ZW; Yu PF; Zhang Z; Gu GL
World J Clin Oncol; 2023 Nov; 14(11):445-458. PubMed ID: 38059189
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Hsu CP; Shen GH; Ko JL
Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
[TBL] [Abstract][Full Text] [Related]
18. Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival.
Viehl CT; Weixler B; Guller U; Dell-Kuster S; Rosenthal R; Ramser M; Banz V; Langer I; Terracciano L; Sauter G; Oertli D; Zuber M
Cancer Med; 2017 May; 6(5):918-927. PubMed ID: 28401701
[TBL] [Abstract][Full Text] [Related]
19. Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.
Stefanovic S; Diel I; Sinn P; Englert S; Hennigs A; Mayer C; Schott S; Wallwiener M; Blumenstein M; Golatta M; Heil J; Rom J; Sohn C; Schneeweiss A; Schuetz F; Domschke C
Ann Surg Oncol; 2016 Mar; 23(3):757-66. PubMed ID: 26467455
[TBL] [Abstract][Full Text] [Related]
20. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]